Exelixis, Inc. (EXEL) Director Lance Willsey Sells 100,000 Shares
Exelixis, Inc. (NASDAQ:EXEL) Director Lance Willsey sold 100,000 shares of Exelixis stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $26.88, for a total value of $2,688,000.00. Following the completion of the transaction, the director now directly owns 518,273 shares of the company’s stock, valued at $13,931,178.24. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Exelixis, Inc. (NASDAQ:EXEL) traded up 1.21% during mid-day trading on Friday, reaching $27.57. The company had a trading volume of 8,048,436 shares. The firm has a 50-day moving average of $27.05 and a 200-day moving average of $23.36. Exelixis, Inc. has a 12-month low of $10.04 and a 12-month high of $29.50. The company has a market capitalization of $8.10 billion, a P/E ratio of 139.24 and a beta of 1.97.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The company had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. During the same period in the prior year, the firm earned ($0.15) earnings per share. Exelixis’s revenue was up 173.1% on a year-over-year basis. On average, equities analysts anticipate that Exelixis, Inc. will post $0.27 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Exelixis, Inc. (EXEL) Director Lance Willsey Sells 100,000 Shares” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/15/exelixis-inc-exel-director-lance-willsey-sells-100000-shares.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. Navellier & Associates Inc bought a new position in Exelixis in the second quarter worth about $1,054,000. Public Employees Retirement System of Ohio raised its stake in Exelixis by 123.7% in the second quarter. Public Employees Retirement System of Ohio now owns 233,322 shares of the biotechnology company’s stock worth $5,747,000 after buying an additional 129,008 shares in the last quarter. Verition Fund Management LLC bought a new position in Exelixis in the second quarter worth about $473,000. California State Teachers Retirement System raised its stake in Exelixis by 14.9% in the second quarter. California State Teachers Retirement System now owns 515,076 shares of the biotechnology company’s stock worth $12,686,000 after buying an additional 66,783 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Exelixis by 1,923.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 263,086 shares of the biotechnology company’s stock worth $6,480,000 after buying an additional 250,086 shares in the last quarter. 79.20% of the stock is owned by institutional investors.
EXEL has been the subject of several research analyst reports. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Cowen and Company reissued an “outperform” rating on shares of Exelixis in a research report on Thursday, August 10th. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price objective for the company in a research report on Tuesday, July 4th. William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $26.00 price objective on shares of Exelixis in a research report on Thursday, September 7th. Five analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.51.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.